Primary CXCR4 Co-receptor use in acute HIV infection leads to rapid disease progression in the AE subtype

Viral Immunology

Volumn 25, Issue 4, 2012, Pages 262-267

  Jiao, Yanmei ^a   Song, Yingxue ^a   Kou, Buxin ^a   Wang, Rui ^a   Liu, Zhiying ^a   Huang, Xiaojie ^a   Chen, Dexi ^a   Zhang, Tong ^a   Wu, Hao ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; VIRUS RNA;

ACUTE DISEASE; ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE COURSE; ENVELOPE GENE; FOLLOW UP; GENE SEQUENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; NONHUMAN;

ACUTE DISEASE; ADULT; CD4 LYMPHOCYTE COUNT; CLONING, MOLECULAR; COHORT STUDIES; DISEASE PROGRESSION; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HOMOSEXUALITY, MALE; HUMANS; MALE; PEPTIDE FRAGMENTS; RECEPTORS, CCR5; RECEPTORS, CXCR4; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; VIRAL TROPISM; YOUNG ADULT;

EID: 84864999588     PISSN: 08828245     EISSN: 15578976     Source Type: Journal    
DOI: 10.1089/vim.2012.0035     Document Type: Article

References (76)

1. Ball JM, Rushlow KE, Issel CJ, and Montelaro RC: Detailed mapping of the antigenicity of the surface unit glycoprotein of equine infectious anemia virus by using synthetic peptide strategies. J Virol 1992;66:732-742.
2. Belshan M, Baccam P, Oaks JL, et al.: Genetic and biological variation in equine infectious anemia virus Rev correlates with variable stages of clinical disease in an experimentally infected pony. Virology 2001;279:185-200.
3. Burns DPW, Collignon C, and Desrosiers RC: Simian immunodeficiency virus mutants resistant to serum neutralization arise during persistent infection of rhesus monkeys. J Virol 1993;67:4104-4113.
4. Carpenter S, Evans LH, Sevoian M, and Chesebro B: In vivo and in vitro selection of equine infectious anemia virus variants. In: Applied Virology Research II: Virus Variation, Epidemiology, and Control. (Kurstak E, Marusyk RG, Murphy FW, and Van Regenmortel MHV, ed.). Plenum Publishing, New York, 1990, pp. 99-115.
5. Carrillo A, and Ratner L: Cooperative effects of the human immunodeficiency virus type 1 envelope variable loops V1 and V3 in mediating infectivity for T cells. J Virol 1996;70: 1310-1316.
6. Cheng-Mayer C, Brown A, Harouse J, Luciw PA, and Mayer AJ: Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVsf33a variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify n-linked glycosylation. J Virol 1999;73:5294-5300.
7. Fouchier RA, Groenink M, Kootstra NA, et al.: Phenotypeassociated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 1992;66:3183-3187.
8. Garrity RR, Rimmelzwaan G, Minassian A, et al.: Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope. J Immunol 1997;159:279-289.
9. Groenink M, Fouchier RA, Broersen S, et al.: Relation of phenotype evolution of HIV-1 to envelope V2 configuration. Science 1993;260:1513-1516.
10. Hammond SA, Cook SJ, Lichtenstein DL, Issel CJ, and Montelaro RC: Maturation of the cellular and humoral immune responses to persistent infection in horses by equine infectious anemia virus is a complex and lengthy process. J Virol 1997;71:3840-3852.
11. Hammond SA, Li F, McKeon BM, Cook SJ, Issel CJ, and Montelaro RC: Immune responses and viral replication in long-term inapparent carrier ponies inoculated with equine infectious anemia virus. J Virol 2000;74:5968-5981.
12. Ho SN, Hunt HD, Horton RM, Pullen JK, and Pease LR: Sitedirected mutagenesis by overlap extension using the polymerase chain reaction. Gene 1989;77:51-59.
13. Hosie MJ, Willett BJ, Klein D, et al.: Evolution of replication efficiency following infection with a molecularly cloned feline immunodeficiency virus of low virulence. J Virol 2002;76:6062-6072.
14. Howe L, Leroux C, Issel CJ, and Montelaro RC: Equine infectious anemia virus envelope evolution in vivo during persistent infection progressively increases resistance to in vitro serum antibody neutralization as a dominant phenotype. J Virol 2002;76:10588-10597.
15. Hwang SS, Boyle TJ, Lyerly HK, and Cullen BR: Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science 1991;253:71-74.
16. Kono Y, Kobayashi K, and Fukunaga Y: Antigenic drift of equine infectious anemia virus in chronically infected horses. Arch Ges Virus Forsch 1973;41:1-10.
17. Kwong PD, Doyle ML, Casper DJC, et al.: HIV-1 evades antibody-mediated neutralization through conformational masking or receptor-binding sites. Nature 2002;420:678-682.
18. Leroux C, Issel CJ, and Montelaro RC: Novel and dynamic evolution of equine infectious anemia virus genomic quasispecies associated with sequential disease cycles in an experimentally infected pony. J Virol 1997;71:9627-9639.
19. Li Y, Svehla K, Louder MK, et al.: Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J Virol 2009;83:1045-1059.
20. Li Y, Svehla K, Mathy NL, Voss G, Mascola JR, and Wyatt R: Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants. J Virol 2006;80:1414-1426.
21. Payne SL, Rausch J, Rushlow K, et al.: Characterization of infectious molecular clones of equine infectious anaemia virus. J Gen Virol 1994;75:425-429.
22. Shioda T, Levy JA, and Cheng-Mayer C: Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1992;89: 9434-9438.
23. Sponseller BA: Equine infectious anemia. In: Current Therapy in Equine Medicine, 5th ed. (Robinson NE, ed.). Mosby, St. Louis, 2003.
24. Sponseller BA, Sparks WO, Wannemuehler Y, et al.: Immune selection of equine infectious anemia virus env variants during the long-term inapparent stage of disease. Virology 363:156-165.
25. Watkins BA, Buge S, Aldrich K, et al.: Resistance of human immunodeficiency virus type 1 to neutralization by natural antisera occurs through single amino acid substitutions that cause changes in antibody binding at multiple sites. J Virol 1996;70:8431-8437.
26. Wei X, Decker JM, Wang S, et al.: Antibody neutralization and escape by HIV-1. Nature 2003;422:307-312.
27. Yamaguchi-Kabata Y, Yamashita M, Ohkura S, Hayami M, and Miura T: Linkage of amino acid variation and evolution of human immunodeficiency virus type 1 gp120 envelope glycoprotein (subtype B) with usage of the second receptor. J Mol Evol 2004;58:333-340.
28. Briggs DR, Tuttle DL, Sleasman JW, and Goodenow MM: Envelope V3 amino acid sequence predicts HIV-1 phenotype (co-receptor usage and tropism for macrophages). AIDS 2000; 14:2937-2939.
29. Casseb J, Montanheiro P, Komninakis S, De Brito A, and Duarte AJ: Human immunodeficiency virus type 1 Brazilian subtype B variant showed an increasing avidity of the anti-V3 antibodies over time compared to the subtype B US/European strain in São Paulo, Brazil. Mem Inst Oswaldo Cruz 2004;99:69-71.
30. Chen Y, Shen C, Wu H, et al.: Biological properties of HIV-1 subtype B isolates from infected Chinese blood donors at different disease stages. Virology 2009;384:161-168.
31. Choi WT, and An J: Biology and clinical relevance of chemokines and chemokine receptors CXCR4 and CCR5 in human diseases. Exp Biol Med (Maywood) 2011;236:637-647.
32. Choe H, Martin KA, Farzan M, Sodroski J, Gerard NP, and Gerard C: Structural interactions between chemokine receptors, gp120 Env and CD4.Semin Immunol 1998;10:249-257. Review.
33. Cornelissen M, Mulder-Kampinga G, Veenstra G, et al.: Syncytium-inducing (SI) phenotype suppression at seroconversion after intramuscular inoculation of a non-syncytiuminducing/ SI phenotypically mixed human immunodeficiency virus population. J Virol 1995;69:1810-1818.
34. Cavarelli M, and Scarlatti G: Phenotype variation in human immunodeficiency virus type 1 transmission and disease progression. Dis Markers 2009;27:121-136.
35. Coakley E, Petropoulos CJ, and Whitcomb JM: Assessing chemokine co-receptor usage in HIV. Curr Opin Infect Dis 2005;18:9-15. Review.
36. De Jong JJ, De Ronde A, Keulen W, Tersmette M, and Goudsmit J: Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: Analysis by single amino acid substitution. J Virol 1992;66:6777-6780.
37. De Wolf F, Hogervorst E, Goudsmit J, et al.: Syncytium-inducing and non-syncytium-inducing capacity of human immunodeficiency virus type 1 subtypes other than B: Phenotypic and genotypic characteristics. WHO Network for HIV Isolation and Characterization. AIDS Res Hum Retroviruses 1994;10:1387-1400.
38. Delgado E, Fernandez-Garcia A,Vega Y, et al.: Evaluation of genotypic tropism prediction tests compared with in vitro co-receptor usage in HIV-1 primary isolates of diverse subtypes. J Antimicrob Chemother 2011.
39. Delobel P, Nugeyre MT, Cazabat M, et al.: Population-based sequencing of the V3 region of env for predicting the coreceptor usage of human immunodeficiency virus type 1 quasispecies. J Clin Microbiol 2007;45:1572-1580.
40. Fiebig EW, Wright DJ, Rawal BD, et al.: Bynamics of HIV viremia and antibody seroconversion in plasma donors: Implications for diagnosis and staging of primary HIV infection. AIDS 2003;17:1871-1879.
41. Fouchier RA, Groenink M, Kootstra NA, Tersmette M, Huisman HG, Miedema F, and Schuitemaker H: Phenotypeassociated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 1992;66:3183-3187.
42. Frange P, Chaix ML, Raymond S, et al.: Low frequency of CXCR4-using viruses in patients at the time of primary nonsubtype-BHIV-1 infection. J ClinMicrobiol 2010;48:3487-3491.
43. Frange P, Galimand J, Goujard C, et al.: High frequency of X4/DM-tropic viruses in PBMC samples from patients with primary HIV-1 subtype-B infection in 1996-2007: The French ANRS CO06 PRIMO Cohort Study. J Antimicrob Chemother 2009;64:135-141.
44. Garrido C, Roulet V, Chueca N, et al.: Evaluation of eight different bioinformatics tools to predict viral tropism in different human immunodeficiency virus type 1 subtypes. J Clin Microbiol 2008;46:887-891.
45. Goodenow MM, and Collman RG: HIV-1 coreceptor preference is distinct from target cell tropism: A dual-parameter nomenclature to define viral phenotypes. J Leukoc Biol 2006; 80:965-972.
46. Gottlieb GS, Heath L, Nickle DC, et al.: HIV-1 variation before seroconversion in men who have sex with men: Analysis of acute/early HIV infection in the multicenter AIDS cohort study. J Infect Dis 2008197:1011-1015.
47. Hoffman NG, Seillier-Moiseiwitsch F, Ahn J, Walker JM, and Swanstrom R: Variability in the human immunodeficiency virus type 1 gp120 Env protein linked to phenotype-Associated changes in the V3 loop. J Virol 2002;76:3852-3864.
48. Isaacman-Beck J, Hermann EA, Yi Y, et al.: Heterosexual transmission of human immunodeficiency virus type 1 subtype C: Macrophage tropism, alternative coreceptor use, and the molecular anatomy of CCR5 utilization. J Virol 2009;83:8208-8220.
49. Jensen MA, Li FS, and van't Wout AB, et al.: Improved coreceptorusage prediction and genotypicmonitoring ofR5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol 2003;77:13376-13388.
50. Jensen MA, and van't Wout AB: Predicting HIV-1 coreceptor usage with sequence analysis. AIDS Rev 2003;5:104-112.
51. Jiao Y, Wang P, Zhang H, Zhang T, Zhang Y, Zhu H, and Wu H: (2011). HIV-1 co-receptor usage based on V3 loop sequence analysis: Preferential suppression of CXCR4 virus post HAART? Immunol Invest 2003;40:597-613.
52. Keele BF, Giorgi EE, Salazar-Gonzalez JF, et al.: Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA 2008;105:7552-7557.
53. Lathey JL, PrattRD, andSpector SA:Appearance of autologous neutralizing antibody correlates with reduction in virus load and phenotype switch during primary infection with human immunodeficiency virus type 1. J Infect Dis 1997;175:231-232.
54. Loftin LM, Kienzle M, Yi Y, and Collman RG: R5X4 HIV-1 coreceptor use in primary target cells: Implications for coreceptor entry blocking strategies. J Transl Med 2011;9(Suppl 1):S3.
55. Long EM, Martin HL Jr, Kreiss JK, et al.: Gender differences in HIV-1 diversity at time of infection. Nat Med 2000;6:71-75.
56. Milich L, Margolin B, and Swanstrom R: V3 loop of the human immunodeficiency virus type 1 Env protein: Interpreting sequence variability. J Virol 1993;67:5623-5634.
57. Pillai S, Good B, Richman D, and Corbeil J: A new perspective on V3 phenotype prediction. AIDS Res Hum Retroviruses 2003;19:145-149.
58. Poveda E, Briz V, Quinones-Mateu M, and Soriano V: HIV tropism: Biagnostic tools and implications for disease progression and treatment with entry inhibitors. AIDS 2006; 20:1359-1367.
59. Raymond S, Delobel P, Chaix ML, et al.: Genotypic prediction of HIV-1 subtype D tropism. Retrovirology 2011;8:56.
60. Raymond S, Delobel P, Mavigner M, et al.: Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism. AIDS 2008;22: F11-F16.
61. Recordon-Pinson P, Soulie C, Flandre P, et al.: Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: The ANRS GenoTropism study. Antimicrob Agents Chemother 2010;54:3335-3340.
62. Resch W, Hoffman N, and Swanstrom R: Improved success of phenotype prediction of the human immunodeficiency virus type 1 from envelope variable loop 3 sequence using neural networks. Virology 2001;288:51-62.
63. Ritola K, Pilcher CD, Fiscus SA, et al.: Multiple V1/V2 env variants are frequently present during primary infection with human immunodeficiency virus type 1. J Virol 2004; 78:11208-11218.
64. Robertson DL, Anderson JP, Bradac JA, et al.: HIV-1 nomenclature proposal. Science 2000;288:55-56.
65. Sabado RL, O'Brien M, Subedi A, et al.: Evidence of dysregulation of dendritic cells in primary HIV infection. Blood 2010;116:3839-3852.
66. Schuitemaker H, van't Wout AB, and Lusso P: Clinical significance of HIV-1 coreceptor usage. J Transl Med 2011; 9(Suppl 1):S5.
67. Seclen E, Garrido C, Gonzalez Mdel M, Gonzalez-Lahoz J, De Mendoza C, Soriano V, and Poveda E: High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists. J Antimicrob Chemother 2010;65:1486-1492.
68. Shaheen F, and Collman RG: Co-receptor antagonists as HIV-1 entry inhibitors. Curr Opin Infect Dis 2004;17:7-16. Review.
69. Sing T, Low AJ, Beerenwinkel N, et al.: Predicting HIV coreceptor usage on the basis of genetic and clinical covariates Antivir Ther 2007;12:1097-1106.
70. Skrabal K, Low AJ, Dong W, Sing T, Cheung PK, Mammano F, and Harrigan PR: Betermining human immunodeficiency virus coreceptor use in a clinical setting: Begree of correlation between two phenotypic assays and a bioinformatic model. J Clin Microbiol 2007;45:279-284.
71. Sucupira MC, Sanabani S, Cortes RM, et al.: Faster HIV-1 disease progression among Brazilian individuals recently infected with CXCR4-utilizing strains. PLoS One 2012;7: E30292.
72. Zhang C, Xu S, Wei J, Guo H: Predicted co-receptor tropism and sequence characteristics of China HIV-1 V3 loops: Implications for the future usage of CCR5 antagonists and AIDS vaccine development. Int J Infect Dis 2009;13:e212.
73. Zhu T, Mo H, Wang N, Nam DS, Cao Y, Koup RA, and Ho DD: Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 1993;261:1179-1181.
74. Vogel T, Kurth R, Norley S: The majority of neutralizing Abs in HIV-1-infected patients recognize linear V3 loop sequences. Studies using HIV-1MN multiple antigenic peptides. J Immunol 1994;153:1895-1904.
75. Cabello A, Cabral M, Vera ME, Kiefer R, Azorero RM, Eberle J, Gü rtler L, Von Brunn A: Analysis of the V3 loop sequences from 10 HIV type 1-infected AIDS patients from Paraguay. AIDS Res Hum Retroviruses 1995;11:1135-1137.
76. Tamura K, Dudley J, Nei M, Kumar S: MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 2007;24:1596-1599.